SNDX Syndax Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why SNDX matters now
Syndax Pharmaceuticals, Inc. (SNDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $19.57 with -0.41% on the session and $1.73B in market capitalization; recent performance reads 1-month -1.86% and YTD -9.57%.
The latest financial table shown here is Q1 2026, with revenue of $64.9M, net income of $-42.7M, and EPS of $-0.49. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -16.5%.
The latest indexable market news headline is "Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?" from Invezz.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.50; recent insider activity includes Botwood Nicholas A.J. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
39.54
P/S
7.75
EV/EBITDA
-11.68
DCF Value
$14.80
FCF Yield
-16.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.0%
Operating Margin
-102.9%
Net Margin
-112.0%
ROE
-256.7%
ROA
-51.5%
ROIC
-57.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $64.9M | $-42.7M | $-0.49 |
| Q4 2025 | $68.5M | $-68.0M | $-0.78 |
| FY 2025 | $172.4M | $-285.4M | $-3.29 |
| Q3 2025 | $45.9M | $-60.7M | $-0.70 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$38.50
Target (Median)
$38.50
Target Range
$31.00 - $46.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.39
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.